Developing new treatments for human cytomegalovirus infections
Official title: Optimization of novel inhibitors of human cytomegalovirus
Funded at Icahn School of Medicine at Mount Sinai · NIH-11125021 · Data updated 2026-11-12
This study is working on new ways to stop the human cytomegalovirus (CMV), which can be really dangerous for people with weakened immune systems, like newborns and organ transplant patients, so they can have safer and better treatment options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 20, 2024 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $683,995 |
| NIH project number | 1R56AI175974-01A1 |
| Project ID | NIH-11125021 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include immunocompromised individuals, such as newborns, organ transplant recipients, and patients with AIDS.
✕Less likely to help
Patients who are not immunocompromised or do not have a history of CMV infection may not benefit from this research.
What this research studies
This research focuses on creating novel inhibitors to combat human cytomegalovirus (CMV), a virus that poses significant risks to immunocompromised individuals, including newborns and organ transplant recipients. The approach involves targeting various stages of the viral life cycle to prevent the virus from spreading and causing severe health issues. By developing new therapeutic strategies, the research aims to address the limitations of existing treatments, which often lead to drug resistance and serious side effects. Patients may benefit from safer and more effective options for managing CMV infections.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for patients suffering from CMV-related diseases.
How similar studies have gone: Previous research has shown promise in developing novel antiviral therapies, indicating potential for success in this area.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Tortorella, Domenico — Icahn School of Medicine at Mount Sinai
- Study coordinator: Tortorella, Domenico
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.